Fisiologia de la Nutricion, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico.
Cirugía Experimental, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico.
BMJ Open Diabetes Res Care. 2020 Mar;8(1). doi: 10.1136/bmjdrc-2019-000948.
Obesity is associated with metabolic abnormalities, including insulin resistance and dyslipidemias. Previous studies demonstrated that genistein intake modifies the gut microbiota in mice by selectively increasing , leading to reduction of metabolic endotoxemia and insulin sensitivity. However, it is not known whether the consumption of genistein in humans with obesity could modify the gut microbiota reducing the metabolic endotoxemia and insulin sensitivity.
45 participants with a Homeostatic Model Assessment (HOMA) index greater than 2.5 and body mass indices of ≥30 and≤40 kg/m were studied. Patients were randomly distributed to consume (1) placebo treatment or (2) genistein capsules (50 mg/day) for 2 months. Blood samples were taken to evaluate glucose concentration, lipid profile and serum insulin. Insulin resistance was determined by means of the HOMA for insulin resistance (HOMA-IR) index and by an oral glucose tolerance test. After 2 months, the same variables were assessed including a serum metabolomic analysis, gut microbiota, and a skeletal muscle biopsy was obtained to study the gene expression of fatty acid oxidation.
In the present study, we show that the consumption of genistein for 2 months reduced insulin resistance in subjects with obesity, accompanied by a modification of the gut microbiota taxonomy, particularly by an increase in the Verrucomicrobia phylum. In addition, subjects showed a reduction in metabolic endotoxemia and an increase in 5'-adenosine monophosphate-activated protein kinase phosphorylation and expression of genes involved in fatty acid oxidation in skeletal muscle. As a result, there was an increase in circulating metabolites of β-oxidation and ω-oxidation, acyl-carnitines and ketone bodies.
Change in the gut microbiota was accompanied by an improvement in insulin resistance and an increase in skeletal muscle fatty acid oxidation. Therefore, genistein could be used as a part of dietary strategies to control the abnormalities associated with obesity, particularly insulin resistance; however, long-term studies are needed.
肥胖与代谢异常有关,包括胰岛素抵抗和血脂异常。先前的研究表明,大豆异黄酮通过选择性增加,从而减少代谢内毒素血症和胰岛素敏感性,来改变小鼠的肠道微生物群。然而,目前尚不清楚肥胖人群摄入大豆异黄酮是否可以通过改变肠道微生物群来降低代谢内毒素血症和胰岛素敏感性。
45 名参与者的稳态模型评估(HOMA)指数大于 2.5,体重指数≥30 且≤40kg/m2,进行了研究。患者被随机分为两组,分别服用(1)安慰剂治疗或(2)大豆异黄酮胶囊(50mg/天),为期 2 个月。采集血样以评估血糖浓度、血脂谱和血清胰岛素。通过胰岛素抵抗的 HOMA 指数(HOMA-IR)和口服葡萄糖耐量试验来确定胰岛素抵抗。2 个月后,评估相同的变量,包括血清代谢组学分析、肠道微生物群,并获得骨骼肌活检以研究脂肪酸氧化的基因表达。
在本研究中,我们表明,大豆异黄酮的摄入可以降低肥胖受试者的胰岛素抵抗,同时改变肠道微生物群的分类,特别是厚壁菌门和拟杆菌门的增加。此外,受试者的代谢内毒素血症降低,5'-腺苷一磷酸激活蛋白激酶磷酸化和骨骼肌脂肪酸氧化相关基因的表达增加。结果,β-氧化和ω-氧化、酰基辅酶 A 和酮体的循环代谢物增加。
肠道微生物群的改变伴随着胰岛素抵抗的改善和骨骼肌脂肪酸氧化的增加。因此,大豆异黄酮可以作为控制与肥胖相关的异常的饮食策略的一部分,特别是胰岛素抵抗;然而,需要进行长期研究。